Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 16, 2023

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights for the fourth quarter and full year 2022.

Read more at globenewswire.com

Related news for (EVLO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.